Manufacturing

Articles

The new software lets users choose the volume and cell concentration from initial cell preparation through transduction to final resuspension, without compromising cell viability and virus stability.

GE Healthcare Life Sciences Launches New Software for Cell Therapy Workflow

The new 50,000-square-foot facility will create 200 new jobs and accelerate commercialization of gene and cell therapies.

Thermo Fisher Scientific Opens $90-Million Viral Vector Manufacturing Site in Massachusetts

Agnes Shanley is senior editor of Pharmaceutical Technology.

Aiming to break the bottlenecks that are slowing commercialization of innovative therapies, a new $50-million center in Boston will develop both cell and viral vector products within a single facility.


New Center Marks Aggressive Push into CGMP Manufacturing of Cell and Gene Therapies

Biopharma company, Zelluna Immunotherapy, and clinical stage biotech, Glycostem Therapeutics, have entered into a partnership focused on the development and manufacture of allogeneic T-cell receptor guided Natural Killer  cell therapies for the treatment of cancer.

Zelluna Immunotherapy and Glycostem Therapeutics Partner on Cell Therapies

Lonza and Cryoport have partnered up to strengthen Lonza’s ‘vein-to-vein’ delivery network by removing supply chain hurdles faced by developers of personalized therapeutics.

Lonza, Cryoport Partner in Cell and Gene Therapy Field

A number of experts will be examining investment opportunities within the evolving cell and gene therapy sector, in a panel discussion on Wednesday morning (Nov. 6, 2019) during CPhI Worldwide in Frankfurt, Germany.

Investing in Cell and Gene Technology

Published on Oct. 29, 2019, the study focuses on the multidrug-resistant bacterium Pseudomonas aeruginosa (P. aeruginosa) and how it can be used to develop new and sustainable antibiotic treatments. 

New Study Reveals How Drug Resistance Could Advance Antibiotic Therapies

The partnership will center on the development and commercialization of DCR-HBVS, Dicerna’s investigational therapy in Phase I clinical development, using its proprietary RNAi platform technology.

Roche and Dicerna Enter Collaboration Worth up to $1.67 Billion

The project will seek to deliver treatments for the underlying cause of cystic fibrosis through submitted proposals from potential collaborators.

Cystic Fibrosis Foundation Announces $500 Million Path to a Cure Research Project

Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.

Manufacturing, Cell Therapies